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Abstract
Background: Human Immunodeficiency Virus/ Hepatitis B Virus (HIV/HBV) co-infection in Nigerian children has
emerged as a major concern with the advent of  HAART. Its impact on the immune system and liver has not been
extensively studied in children.
Objectives: To determine the prevalence of  HBV seropositivity among HIV positive children on HAART and its effect on
immune response and liver enzymes.
Methods: All consecutive HIV positive children aged two months to seventeen years on HAART constituted the study
population. Age and gender; CD4+ count, ALT, creatinine and HBsAg were tested and documented at enrolment and
12months.
Results: One hundred and seventy one patients were seen over this period. Seventy-two (43.4%) were males while 94
(56.6%) were females giving a male: female ratio of 1:1.3. The mean age of the patients was 63±43.4 months. Prevalence of
HIV/HBV co-infection was 6.02% (95% CI 2.4-9.7). There was no significant effect of  HBV status on elevation of  ALT
levels with 12 months of  HAART. Co-infected patients had an odds ratio of  achieving immune response of  0.14 (95% CI
0.02-0.79).
Conclusion: HIV/HBV co-infection rates in our children are comparable to other localities. ALT levels do not worsen with
HAART and immune response of the co-infected children on HAART is lower.
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Nigeria has the greatest burden of paediatric HIV/
AIDS in sub-Saharan Africa despite a national
seroprevalence of 4.6%.1, 2  There are over 240,000
children living with HIV/AIDS, representing 15%
of the African burden.3 The rate of vertical
transmission is as high as 25%-42% in African
countries. An estimated 600,000 new paediatric
infections occur each year, with over 90% of these
cases occurring in sub-Saharan Africa.4 Rapid
progression of  HIV-1 infection to Acquired Immune
Deficiency Syndrome (AIDS) is also a major
problem in these children. Up to 25% of prenatally
infected infants progress to AIDS within one year
and the remaining 75% within a median period of
seven years.5
Nigeria belongs to the group of countries
highly endemic for hepatitis B virus (HBV) infection,6,
7 a virus that shares common modes of transmission
with HIV. 8 One of  the major determinants of
accelerated HIV disease progression is the presence
of  co-morbidities and opportunistic infections. The
epidemiology, natural history and treatment of  HIV
co-infection with HBV has been studied extensively
in adults9-13 and documented sparingly in children,14-
16 more so among Nigerian children. In Tanzania
and Cote d’Ivoire, the prevalence rates of the co-
infection has been reported as 1.2%14 and 12.1%17
respectively while among Nigerian children, it is 8.3%.
18
HBV infection is known to lead to chronic
infection after the acute infection especially if acquired
in the perinatal period and early childhood.6,19 With
improved survival due to the success of  highly active
antiretroviral therapy (HAART), chronic viral
hepatitis has become a major source of co morbidity
in HIV infected populations.20 In adults, co-infection
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with HBV increases the risk for hepatotoxicity of
HAART and likelihood of onset of an AIDS-
defining illness, compared to infection with HIV-1
alone.21  It is not certain whether this is the case with
children.
Most studies on co-infection in Nigeria have
been in adults. With increasing access to HAART in
Nigeria, it is expected that more HIV infected and
co-infected children will survive. Although HIV co-
infection with HBV has been recognised worldwide,
there is limited data on the impact of this co-infection
on the immune system. Data on its effect on the
liver with HAART is also limited in developing
countries like Nigeria. It is therefore imperative that
the burden of this co-infection is quantified and its
attendant effect investigated.
This study was therefore carried out to
determine the prevalence of  HBV seropositivity in
a cohort of paediatric patients living with HIV/AIDS
in a tertiary hospital in south-south Nigeria. The
effect of co-infection on CD4+ lymphocytes and
liver enzymes in the HAART era were also examined.
Methods
This prospective longitudinal study was conducted
in the Infectious Disease Unit (IDU) of the
Department of Paediatrics, University of Uyo
Teaching Hospital (UUTH), Uyo, from December
2010 to August 2011. The hospital is the only tertiary
and referral centre in Uyo, capital city of  Akwa Ibom
State of Nigeria. It is also the main centre for
Paediatric HIV care. It serves the 3.9 million
population of the State.
The study was approved by the University of Uyo
Teaching Hospital Research and Ethics Committee.
The IDU runs a weekly Paediatric HIV/
AIDS clinic. It is one of  the President’s Emergency
Plan Funds for AIDS Relief  (PEPFAR) sites where
antiretroviral drugs are given and investigations are
carried out at no cost to the patient. The baseline
investigations that are conducted before
commencement of HAART include CD4+ count,
full blood count, electrolytes, creatinine, urea, and
liver function tests. Eligibility criteria for
commencement of HAART included all children
less than 24 months irrespective of the CD4+ cell
count; CD4+ cell count < 750 in children aged 25
months to 59 months, < 350 for 60 months and
above and any child seen at clinical stage 3 or 4.
Eligible patients were commenced on
HAART and were seen on a regular basis at the clinic.
HAART comprised at least two drugs from the
Nucleoside reverse transcriptase inhibitor (NRTIs)
class of antiretroviral drugs and one from the Non-
nucleoside reverse transcriptase inhibitor class
(NNRTIs). The first line drugs used included
Lamivudine (3TC), Zidovudine (AZT) and
Nevirapine (NVP) as fixed dose combination. At
follow up visits, they received general paediatric care
with full physical examination and anthropometric
measurements taken. Their CD4+ counts and full
blood count were monitored on a 3-monthly basis,
while electrolytes, creatinine, urea and liver function
tests were monitored biannually. All consecutive
children aged two months to seventeen years that
were confirmed to be HIV positive during the study
period were enrolled.
Informed consent was obtained from the
parent/guardian prior to enrolment. Children older
than 10 years also gave a verbal consent.
Confirmation was by enzyme – linked
immunosorbent assay (ELISA) in those older than
18months or by DNA polymerase chain reaction
(PCR) for those younger than 18 months. HIV RNA
viral load and HBV DNA viral load were not done
as our facility didn’t have the equipment for these
tests at the time of  the study.
All children that were not eligible for
HAART (five in all) were excluded from subsequent
analysis after the prevalence of co-infection among
the HIV positive was obtained. CD4+ cell count
and HBsAg tests were done at enrolment and one
week after if  they were eligible for HAART, and
baseline investigations were carried out. Thereafter,
the patients had an average of three adherence
counselling sessions within a period of two weeks
before initiation of  HAART.
Demographic information (age and sex),
results of investigations (CD4+ count, alanine
aminotransferase, and creatinine) were obtained and
documented.
HBsAg was tested using First Response
Rapid HBsAg test (Blumber B. S. 1991, San Diego,
USA). For CD4+ count, Flow Cytometry using
Partec cyflow counter (Greve, B. Et al 2003,
Germany) was used. All the chemistry was done
using the in vitro quantitative analysis method using
Vitros DT 60 11 chemistry system (Johnson &
Johnson). All assay protocols, cut-offs and
interpretation were according to the manufacturer’s
instructions.
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A gender comparison of the clinical,
biochemical characteristics and HBV prevalence of
the participants was done. The prevalence of HBV
in each of the age groups was also explored. The
proportion of  those with elevated ALT levels (> 2
times upper limit of reference range for our
laboratory which was 70 iu/l ) by co-infection status
was computed and univariate and multivariate logistic
regression models were used to investigate the effect
of  HBV status on having elevated serum ALT at
commencement of  HAART. Immune response was
defined as the achievement of at least 50 cells/µL
increments in CD4 count from baseline at 12 months
of  therapy. The effect of  co-infection on achieving
immune response was also investigated using
multivariate logistic regression. All factors with a p-
value of  the Wald statistic < 0.25 at univariate analysis
or known to have potential effect on immune
response were included in the multivariate model
built using stepwise regression.
Results
One hundred and sixty six (166) paediatric patients
were seen over this period. Seventy – two (43.4%)
were males while 94 (56.6%) were females giving a
male:female ratio of 1:1.3. The mean age of the
patients was 63 ± 43.4 months.  The mean duration
on Highly active antiretroviral therapy (HAART) was
24.2±18.1 months. Table 1 shows the baseline
characteristics of  the study participants. Those aged
2- 23 months were 30 (18.1%), 24 – 60 months
were 67 (40.4 %), 61 – 120 months 48 (28.9%) and
> 120 months were 21 (12.6%).
Prevalence of  HIV-HBV co-infection
Ten (6.02%) (95% CI 2.4 to 9.7% ) of  the patients
had HIV – HBV co-infection. There was no
significant difference in the prevalence of HBV in
both genders. Four (5.8%) of  the females were HBV
positive compared to 6 (6.7%) of the males, p =
0.54. With regards to age groups, the highest
prevalence was found in the 10 years group (11.5%),
followed by the 5 - 10 years age group (9.3% ).
There was no association between age and HBV co
–infection (p=0.47). A comparison of the
sociodemographic and clinical characteristics of those
with HIV-HBV co-infection with those with only
HIV infection is shown in Figure 1 and table 2.
Individuals with HBV co-infection had higher serum
creatinine levels and lower CD4 cell counts at baseline
and at 12 months of  therapy.
Table 1: Gender distribution of  baseline characterisitics
Total Male Female p - value
Age 63.0±43.4 61.9±41.1 64.3±46.4 0.75
ALT (U/L) 42 (31 – 58) 38.5 (29 – 56) 45 (34 – 60) 0.12*
Creatinine (umol/L) 44.5±20.1 44.5±20.7 44.4±19.3 0.98
Baseline CD4     count(cells/uL) 503 (233 – 860) 468 (232 – 822) 591.5 (264.5 – 957)  0.44*
































Graphs by hepatitis B virus status
Figure 1: Graph box showing CD4 count by HBV status
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Table 2: Comparison of  sociodemographic and clinical characteristics by HBV status
Hepatitis B status p - value
Negative Positive
Male gender (n/%) 83 (56.1) 6 (60) 0.81
Age (months) 61.8±42.5 83.9±49.9 0.12
ALT (U/L) 42 (31 – 56) 50 (30 – 70) 0.49
Creatinine (umol/L) 42.5 (32 – 50) 54.5 (45 – 56) 0.02
CD4 count at baseline (cells/uL) 529 (249 – 861) 149 (53 – 232) 0.0003
CD4 count at 6 months of HAART 893 (560 – 1245) 318 (83 – 566) 0.0004
Influence of  Hepatitis B status on ALT levels
At the commencement of  HAART, 66 (39.8%) of
the children had elevated serum ALT levels;  (70% of
the co-infected children and 58.1% of the HIV only
group ) but this difference was not statistically
significant (p = 0.46). Only four of the children had
ALT levels greater than two times the upper limit of
normal and all were Hepatitis B negative. A
multivariate logistic regression model did not show
any significant effect of HBV status on development
of  elevated ALT levels one year after commencement
of HAART (see table 3). However, male gender
appeared to be protective against having elevated ALT
levels and those with elevated ALT levels at
commencement of HAART were more prone to
developing higher ALT levels while on therapy.
Influence of  HBV/HIV co-infection on immune
response
Seventy percent of the co-infected and 84.5% of the
mono-infected patients achieved immune response at
12 months of  therapy. A second logistic regression
model was used to assess the effect of HBV/HIV
co-infection on achievement of immune response.
The findings are summarized in Table 4. Those with
HIV/HBV co-infection have an odds ratio of
achieving immune response of 0.14 (95% CI 0.02 –
0.79) after correcting for CD4 count at baseline, age,
gender, BMI, ALT and serum creatinine levels.
Table 3: Association between elevated ALT level and HBV status
Univariate                                           Multivariate
Odds ratio (95%) CI,  Odds ratio (95%) CI,
p - value p - value
Positive HBV status 1.74 (0.48 – 6.29) 0.40 0.97 (0.08 – 12.58) 0.98
Male gender 0.14 (0.07 – 0.29) <0.001 0.01 (0.002 – 0.07) <0.001
Age (months) 1.00 (0.99 – 1.01) 0.94 0.99 (0.97 – 1.01) 0.33
CD4 count at baseline (100 cells/UL) 0.99 (0.98 – 1.00) 0.24 0.98 (0.97 – 0.99) 0.048
Serum creatinine (umol/L) 1.00 (0.98 – 1.02) 0.58 1.00 (0.97 – 1.04) 0.11
ALT (U/L) 1.11 (1.07 – 1.15) <0.001                 1.17 (1.10 – 1.24) <0.001
*The area under the Receiver Operator Characteristic (ROC) Curve of  the model was 0.82
Table 4: Univariate and Multivariate logistic models for predictors of  immune response
Univariate Multivariate*
Odds ratio (95%CI) p-value Odds ratio (95%CI) p-value
Positive HBsAg 0.43 (0.10 – 1.78) 0.24 0.14 (0.02 – 0.79) 0.03
CD4/100 cells/µL 0.98 (0.97 – 0.99) <0.001 0.98 (0.97 – 0.99)
Female gender 0.95 90.41 – 2.21) 0.91 0.58 (0.20 – 1.66) 0.31
ALT (U/L) 1.01 (0.99 – 1.03) 0.25 1.01 (0.98 – 1.03) 0.54
BMI 1.01 (0.84 – 1.21) 0.93 1.08 (0.85 – 1.35) 0.58
Age (months) 1.01 (0.99 – 1.02) 0.25 1.00 (0.99 – 1.02) 0.65
Creatinine (µmol/L) 0.99 (0.97 – 1.01) 0.26 0.98 (0.96 – 1.01) 0.16
* The area under the Receiver Operator Characteristic (ROC) Curve of  the model was 0.80
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Discussion
HAART has transformed HIV/AIDS from a
uniformly fatal illness into a manageable chronic
infection and has been shown to be able to restore
CD4+ cells in HIV infected patients. 22 The gains of
HAART could be compromised by co-infection
with hepatitis viruses as they are known to have
adverse effects on the prognosis of HIV and hepatitis
infections. 23 Consequently, increased attention has
to be paid to co-infection of hepatitis viruses and
HIV.
In this study, the HIV/HBV co-infection
rate of 6.02% is comparable to the 7.7% and 8.3%
obtained from other Nigerian studies.18,24 It is however
lower than the 12.1%17 from a neighbouring west
African country of Cote d’ Ivoire but higher than
rates of 1.2%14 and 4%13 from some east African
countries. A study from Bronx, New York reported
a prevalence of 2.6%.16 These differences may reflect
the seroprevalent rates of HBsAg in the different
populations. Although some Nigerian studies quoted
HBsAg rates as high as 44.7%, the inclusion of
Hepatitis B vaccine in the National Programme on
Immunization (NPI) in the past decade has reduced
the population prevalence and consequently reduced
the HIV/HBV co-infection prevalence.
The finding that the mono and co-infected
patients shared similar demographic characteristics
with respect to age and sex was also reported by
other authors. 14, 16, 24 The mean age of  the co-infected
patients, however, was higher  in this study. The
Bronx, New York study also identified more
adolescents to be co-infected. This may be attributed
to the fact that children in this age group were
exposed before the current prevention strategies were
available( inclusion of HBV in the NPI schedule in
2004). In contrast, Sadoh and coworkers24 concluded
that immunization did not make any significant
difference in the prevalence of co-infection. This
conclusion, however, is presumptuous because they
analysed only the hepatitis B immunization history
of the under-five instead of the whole study
population.
The higher level of the liver enzyme, alanine
aminotransferase (ALT) in the co-infected group was
also reported by other workers.14, 16 This is expected
since hepatitis viruses are known to elevate liver
enzymes.26 We found no association between
HAART and elevated ALT. This is similar to the
findings of  Telatela et al 14 and Toussi et al 16 but
contrasts reports from other studies. 27-29 Our patients
were on first line regimen which comprises
lamivudine, zidovudine and nevirapine. It has been
reported that lamivudine as a component of
HAART, has a beneficial effect in that it causes
inhibition of HBV replication in adherent patients8.
Other drugs that have this beneficial effect are
tenofovir and emtricitabine30. On the contrary,
patients on protease inhibitors are at risk of
developing a worsening of the liver disease since
they are associated with more risk of  elevated ALT
than other antiretroviral drugs. 29
As reported by other authors14, 16 in their
study of paediatric patients, our co-infected patients
had significantly lower CD4+ cell counts compared
to the mono-infected group. However, these authors
did not study the effect of HAART on the CD4 cell
count. We noted that the co-infected patients were
less likely to achieve immune response even with
HAART for one year. This calls for establishment
of a treatment protocol for HIV/HBV co-infected
patients which includes at least two of the anti-
retroviral drugs that induce suppression of HBV
replication, as first line regimen. This will reduce the
hepatotoxic effect of the viruses, improve immune
response as well as prevent development of
resistance on prolonged use of lamivudine alone.
 In contrast, in the adult population, Lincoln
and co-workers31 on behalf of the Australian HIV
Observational Database, reported that co-infection
with HBV did not appear to influence CD4 count
recovery following commencement of  HAART.
Their work involved a larger group of participants
(2089) and the immune response was also checked
after 12 months of  HAART. Our study appears to
be the first to examine this issue in Nigerian children.
Conclusion
We have demonstrated that co-infection of  HIV with
HBV exists in our local at rates that are comparable
with those of  other communities. We have also
shown that HAART does not worsen ALT levels
and that the immune response of the co-infected
patients is lower with treatment compared to the
mono-infected patients.
Recommendations
We therefore recommend that screening for HBsAg
be mandatory in all paediatric HIV patients in our
environment, especially the adolescents. They should
receive special attention with regards to, the
antiretroviral drugs they are treated with, monitoring
and follow up to assess disease progression.
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The limitations of this study include the inability of
our laboratory to carry out HIV RNA viral load
and the HBV DNA viral load. Further studies with
determination of  viral loads are advocated.
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